End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
57.16 CNY | -0.24% | +3.27% | -16.15% |
Apr. 29 | Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 62 Yuan From 87 Yuan, Keeps at Hold | MT |
Apr. 26 | Yunnan Botanee Bio-Technology Group Co.LTD Proposes Final Dividend for 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 67% by 2026.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.15% | 3.32B | C+ | ||
-2.01% | 254B | B- | ||
+12.81% | 19.89B | B+ | ||
0.00% | 18.26B | - | - | |
+0.38% | 11.16B | A- | ||
-7.61% | 10.38B | A- | ||
+16.34% | 7.63B | B+ | ||
+16.25% | 5.97B | B | ||
+2.43% | 4.65B | B+ | ||
-16.92% | 3.81B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300957 Stock
- Ratings Yunnan Botanee Bio-Technology Group Co.LTD